Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

This work can lay foundation to so much more! #ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups - Mental health mentioned in 4% of all posts/comments - primary care asso with “trust” and urgent care with “fear” @RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg

Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089 Continued under-reporting of race and ethnicity in PsA trials. Abs 0090 We can do better #rheumtwitter #ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg

• Racial Disparities in Rheumatology Clinical Trials - ACR Meeting Abstracts
• Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis -…

#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu

Abst#0001 MIRROR RCT at #ACR22 #plenary Pts with gout on #pegloticase and #gout sustained higher urate lowering response in pts cotreated with #MTX benefit beyond 6 months @rheumnow https://t.co/rTZ3fPaFJS

🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC

Excellent start to the first plenary session! MIRROR study - MTX coadministration with pegloticase for gout treatment - doubling of efficacy and 7x decrease in infusion reactions - less anti-PEG abs @RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO